InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Empiricst1 PremiumMember
08/01/18 4:25 AM
profile icon
gajj Free
07/30/18 7:34 PM
profile icon
Traderjohn7 Free
02/25/18 3:43 PM
profile icon
bill_y Free
02/25/18 10:45 AM
profile icon
Traderjohn7 Free
02/24/18 4:19 PM
profile icon
Traderjohn7 Free
02/23/18 3:37 PM
profile icon
raja48185 Free
02/22/18 3:34 PM
profile icon
bill_y Free
12/31/17 6:19 PM
profile icon
Easymoneyman00 Free
12/31/17 12:21 AM
profile icon
bill_y Free
11/18/17 9:31 AM
profile icon
Traderjohn7 Free
11/15/17 12:05 PM
profile icon
bill_y Free
09/01/16 1:59 PM
profile icon
jaxstraw Free
09/01/16 7:03 AM
profile icon
bill_y Free
08/31/16 2:12 PM
profile icon
jaxstraw Free
08/31/16 12:42 PM
profile icon
stocktrademan Free
08/26/16 10:49 AM
profile icon
stocktrademan Free
08/22/16 11:42 AM

Advaxis, Inc. Warrants (ADXSW) RSS Feed

Followers
2
Posters
9
Posts (Today)
0
Posts (Total)
22
Created
08/22/16
Type
Free
Moderators
Advaxis, Inc. 305 College Road East Princeton, NJ 08540 United States 609-452-9813 http://www.advaxis.com Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. Its lead product Axalimogene filolisbac (ADXS-HPV), an Lm-LLO immunotherapy product candidate, which completed its Phase II study used for the treatment of human papilloma virus (HPV) associated cancers, including cervical, head and neck, and anal cancer. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen (PSA) antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) expressing cancers, including human and canine osteosarcoma, breast, gastric, and other cancers. It has clinical trial collaboration agreements with Merck & Co., Inc. for the Phase I/II dose-escalation and safety study of ADXS31-142; MedImmune, LLC to initiate a Phase I/II clinical study in the United States to evaluate the safety and efficacy of MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor in combination with ADXS-HPV; and Incyte Corporation for the development and analysis of a combination therapy for the treatment of cervical cancer. The company also has a licensing agreement with Global BioPharma, Inc.; development and commercialization agreement with Especificos Stendhal SA de CV.; and collaboration agreement with Amgen Inc. for the development and commercialization of Advaxis' ADXS-NEO, a preclinical investigational cancer immunotherapy treatment that activates patient's immune system to respond against mutations and neoepitopes. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
ADXSW Latest News
  • No Recent News Available for this company!
New Post